Advances in PSMA-targeted Therapy for Prostate Cancer

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2021 May 29

PMID 34050265

Citations 32

Authors

Fujin Wang

Zhifeng Li

Xiaoqian Feng

Dazhuang Yang

Mei Lin

Affiliations

Soon will be listed here.

Abstract

Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein located on the cell membrane, is specifically and highly expressed in prostate cancer (PCa). Besides, its expression level is related to tumor invasiveness. As a molecular target of PCa, PSMA has been extensively studied in the past two decades. Currently, a great deal of evidence suggests that significant progresses have been made in the PSMA-targeted therapy of PCa. Herein, different PSMA-targeted therapies for PCa are reviewed, including radioligand therapy (Lu-PSMA-RLT, Ac-PSMA-RLT), antibody-drug conjugates (MLN2704, PSMA-MMAE, MEDI3726), cellular immunotherapy (CAR-T, CAR/NK-92, PSMA-targeted BiTE), photodynamic therapy, imaging-guided surgery (radionuclide-guided surgery, fluorescence-guided surgery, multimodal imaging-guided surgery), and ultrasound-mediated nanobubble destruction.

Citing Articles

Targeting Surface Markers in Anaplastic Thyroid Cancer: Future Directions in Ligand-bound Therapy.

Pakkianathan J, Chan S, Cruz J, Ewan K, Simental A, Khan S J Endocr Soc. 2025; 9(4):bvaf035.

PMID: 40071065 PMC: 11893542. DOI: 10.1210/jendso/bvaf035.

PSMA PET/CT for early treatment response assessment of RANKL inhibitor therapy in giant cell tumor of bone.

Zhang W, Shen G Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40059185 DOI: 10.1007/s00259-025-07194-2.

Iodinated PSMA Ligands as XFI Tracers for Targeted Cell Imaging and Characterization of Nanoparticles.

Kerpa S, Holzapfel M, Staufer T, Kuhrwahl R, Mutas M, Werner S Int J Mol Sci. 2024; 25(22).

PMID: 39595950 PMC: 11594147. DOI: 10.3390/ijms252211880.

Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer.

Cordova R, Sommers N, Law A, Klunk A, Brady K, Goodrich D Sci Signal. 2024; 17(864):eadp1375.

PMID: 39591412 PMC: 11826925. DOI: 10.1126/scisignal.adp1375.

The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge.

Zeng T, Xie Y, Chai K, Sang H Onco Targets Ther. 2024; 17:991-1015.

PMID: 39564453 PMC: 11573878. DOI: 10.2147/OTT.S485869.

References

Xiang J, Yan H, Li J, Wang X, Chen H, Zheng X . Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019; 17(1):31. PMC: 6375152. DOI: 10.1186/s12957-019-1573-0. View

Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M . Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018; 45(5-6):303-315. DOI: 10.1053/j.seminoncol.2018.10.001. View

Nizialek E, Antonarakis E . PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. Cancer Manag Res. 2020; 12:8105-8114. PMC: 7489946. DOI: 10.2147/CMAR.S227033. View

Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito Jr P, Wang C . Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006; 30(4):628-36. DOI: 10.1007/s00268-005-0544-5. View

Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F . New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. Front Oncol. 2019; 8:653. PMC: 6308151. DOI: 10.3389/fonc.2018.00653. View

Aloysius H, Hu L . Targeted prodrug approaches for hormone refractory prostate cancer. Med Res Rev. 2014; 35(3):554-85. DOI: 10.1002/med.21333. View

Pastorino S, Riondato M, Uccelli L, Giovacchini G, Giovannini E, Duce V . Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications. Curr Radiopharm. 2019; 13(1):63-79. PMC: 7509769. DOI: 10.2174/1874471012666190729151540. View

Bander N, Trabulsi E, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P . Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003; 170(5):1717-21. DOI: 10.1097/01.ju.0000091655.77601.0c. View

Wang A, Farokhzad O . Current progress of aptamer-based molecular imaging. J Nucl Med. 2014; 55(3):353-6. PMC: 4110511. DOI: 10.2967/jnumed.113.126144. View

10.

Hussain A, Tur M, Barth S . An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin. Nucleic Acid Ther. 2013; 23(3):203-12. DOI: 10.1089/nat.2012.0408. View

11.

Lupold S, Hicke B, Lin Y, Coffey D . Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002; 62(14):4029-33. View

12.

Dassie J, Liu X, Thomas G, Whitaker R, Thiel K, Stockdale K . Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009; 27(9):839-49. PMC: 2791695. DOI: 10.1038/nbt.1560. View

13.

Rockey W, Hernandez F, Huang S, Cao S, Howell C, Thomas G . Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011; 21(5):299-314. PMC: 3198747. DOI: 10.1089/nat.2011.0313. View

14.

Hillier S, Maresca K, Femia F, Marquis J, Foss C, Nguyen N . Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69(17):6932-40. PMC: 4114247. DOI: 10.1158/0008-5472.CAN-09-1682. View

15.

Bouchelouche K, Turkbey B, Choyke P . PSMA PET and Radionuclide Therapy in Prostate Cancer. Semin Nucl Med. 2016; 46(6):522-535. PMC: 5123597. DOI: 10.1053/j.semnuclmed.2016.07.006. View

16.

Baum R, Kulkarni H, Schuchardt C, Singh A, Wirtz M, Wiessalla S . 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016; 57(7):1006-13. DOI: 10.2967/jnumed.115.168443. View

17.

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E . Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015; 5(1):114. PMC: 4477007. DOI: 10.1186/s13550-015-0114-2. View

18.

Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E . Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017; 44(9):1448-1454. DOI: 10.1007/s00259-017-3716-2. View

19.

Hofman M, Violet J, Hicks R, Ferdinandus J, Thang S, Akhurst T . [Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018; 19(6):825-833. DOI: 10.1016/S1470-2045(18)30198-0. View

20.

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang S, Kong G . Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2019; 61(6):857-865. PMC: 7262220. DOI: 10.2967/jnumed.119.236414. View